New hope for kids with Tough-to-Treat leukemia
NCT ID NCT07437170
Summary
This study is testing whether adding a drug called selinexor to standard chemotherapy works better for children with a specific, high-risk type of acute myeloid leukemia (AML) linked to a gene called NUP98. The goal is to see if this combination helps more children achieve remission and live longer. The trial is for up to 10 children who have this specific genetic form of AML.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Children's Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310000, China
Conditions
Explore the condition pages connected to this study.